Key result
Indobufen significantly reduced the average number and incidence of transient ischaemic attacks after 1 month of treatment (P<0.001), remaining suppressed throughout the 12-month period.
Why the study?
Does indobufen reduce the incidence of transient ischaemic attacks in patients requiring secondary prevention?
Does indobufen reduce the incidence of transient ischaemic attacks in patients requiring secondary prevention?
Indobufen 100 mg twice daily significantly reduces the incidence of transient ischaemic attacks over 12 months and is generally well tolerated.
Indobufen was associated with fewer TIAs in this cohort; leaves open efficacy for secondary prevention pending randomized trials.
The secondary prevention of transient ischaemic attacks was assessed in 270 patients treated orally with 100 mg indobufen given twice daily for 12 months. After 1 month's treatment, the average number and average incidence of transient ischaemic attacks were reduced significantly (P less than 0.001) and remained suppressed throughout the treatment period. Treatment was interrupted in 17 patients: in two because of side-effects (gastric disturbances); in 10 because of fatal events (six completed strokes, two myocardial infarcts and two unrelated deaths); and in five due to poor protocol compliance. Progression to reversible ischaemic neurological deficit occurred in five patients. Most side-effects were mild and transient, mainly occurring in the first month of treatment. Overall, indobufen was judged to have good efficacy and safety by both patients and physicians.
No takes yet. Share an insight, caveat, or question.
J. M. Rogan (1990) studied Transient Ischaemic Attack (n=270). Indobufen was evaluated on Average number and average incidence of transient ischaemic attacks (p=<0.001). Indobufen significantly reduced the average number and incidence of transient ischaemic attacks after 1 month of treatment (P<0.001), remaining suppressed throughout the 12-month period.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: